| Literature DB >> 21575859 |
Brett S Carver1, Caren Chapinski, John Wongvipat, Haley Hieronymus, Yu Chen, Sarat Chandarlapaty, Vivek K Arora, Carl Le, Jason Koutcher, Howard Scher, Peter T Scardino, Neal Rosen, Charles L Sawyers.
Abstract
Prostate cancer is characterized by its dependence on androgen receptor (AR) and frequent activation of PI3K signaling. We find that AR transcriptional output is decreased in human and murine tumors with PTEN deletion and that PI3K pathway inhibition activates AR signaling by relieving feedback inhibition of HER kinases. Similarly, AR inhibition activates AKT signaling by reducing levels of the AKT phosphatase PHLPP. Thus, these two oncogenic pathways cross-regulate each other by reciprocal feedback. Inhibition of one activates the other, thereby maintaining tumor cell survival. However, combined pharmacologic inhibition of PI3K and AR signaling caused near-complete prostate cancer regressions in a Pten-deficient murine prostate cancer model and in human prostate cancer xenografts, indicating that both pathways coordinately support survival.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21575859 PMCID: PMC3142785 DOI: 10.1016/j.ccr.2011.04.008
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743